Medicare Enrolled
Dr. Manish Shah, MD
Medical Oncology · New York, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Manish Shah is a medical oncology specialist in New York, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Shah performed 37,673 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Shah received a total of $304,792 from 34 pharmaceutical and/or device companies across 213 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 3% volume in NY
$304,792 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗37,673
Medicare services
Top 3% in NY for medical oncology
Not available
Unique patients (not deduplicated)
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
30,460 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,011 | $1 | $55 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,471 | $2 | $10 |
| Injection, leucovorin calcium, per 50 mg | 700 | $3 | $15 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
680 | $160 | $550 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
642 | $0 | $2 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
342 | $14 | $100 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
303 | $119 | $565 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
173 | $111 | $620 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
168 | $17 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
118 | $59 | $280 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
116 | $25 | $150 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
89 | $45 | $250 |
| New patient office visit, complex (60-74 min) | 49 | $187 | $700 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
45 | $8 | $35 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
45 | $27 | $150 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
42 | $113 | $425 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
39 | $22 | $100 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
38 | $107 | $350 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
28 | $2 | $25 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
24 | $1 | $50 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
22 | $32 | $225 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
22 | $22 | $95 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
17 | $56 | $260 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
16 | $158 | $650 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
13 | $12 | $100 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.8% high complexity
95.6% medium
2.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$304,792
Total received (2018-2024)
Avg $43,542/year across 7 years
Top 5% in NY for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
213
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$54,216
2023
$23,966
2022
$12,807
2021
$50,545
2020
$42,923
2019
$80,721
2018
$39,614
Payments by company (2024)
E.R. Squibb & Sons, L.L.C.
$13,262
Merck Sharp & Dohme LLC
$10,934
BeiGene USA, Inc.
$10,232
Regeneron Pharmaceuticals, Inc.
$7,344
Eisai Inc.
$4,710
ABBVIE INC.
$3,018
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,220
Coherus Biosciences Inc.
$1,200
Gilead Sciences, Inc.
$960
AstraZeneca Pharmaceuticals LP
$194
Novartis Pharmaceuticals Corporation
$63
Genentech, Inc.
$28
Ipsen Biopharmaceuticals, Inc
$27
TerSera Therapeutics LLC
$23
Top 3 companies account for 63.5% of 2024 payments
All-time payments by company (2018-2024) ›
Merck Sharp & Dohme Corporation
$102,342
E.R. Squibb & Sons, L.L.C.
$39,938
Lilly USA, LLC
$26,026
Daiichi Sankyo Inc.
$18,099
Eli Lilly and Company
$12,560
Merck Sharp & Dohme LLC
$10,934
F. Hoffmann-La Roche AG
$10,771
Takeda Pharmaceuticals U.S.A., Inc.
$10,704
BeiGene USA, Inc.
$10,232
GENZYME CORPORATION
$8,930
EMD Serono, Inc.
$7,800
Regeneron Pharmaceuticals, Inc.
$7,344
Eisai Inc.
$4,710
Coherus Biosciences Inc.
$4,200
ARRAY BIOPHARMA INC
$4,028
AstraZeneca UK Limited
$3,934
ABBVIE INC.
$3,018
AstraZeneca Pharmaceuticals LP
$2,480
Janssen Research & Development, LLC
$2,430
Astellas Pharma US Inc
$2,325
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,220
GlaxoSmithKline, LLC.
$1,950
Boehringer Ingelheim RCV GmbH & Co KG
$1,634
Novartis Pharmaceuticals Corporation
$1,626
PFIZER INC.
$1,328
Celularity Inc.
$1,000
Gilead Sciences, Inc.
$960
Ipsen Biopharmaceuticals, Inc
$670
Janssen Global Services, LLC
$270
ImClone Systems, LLC
$213
Advanced Accelerator Applications
$36
Amgen Inc.
$29
Genentech, Inc.
$28
TerSera Therapeutics LLC
$23
Top 3 companies account for 55.2% of all-time payments
Associated products mentioned in payments ›
Avastin · CREON · CYRAMZA · Enhertu · FRUZAQLA · KEYTRUDA · Kadcyla · LENVIMA · LOQTORZI · LUMAKRAS · LUTATHERA · Lenvima · Lutathera · MEKTOVI · OPDIVO · Onivyde · Perjeta · SOMATULINE DEPOT · TEVIMBRA · Xermelo
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
355
County median income
$104,553
Nearest hospital to ZIP centroid (approximate)
HOSPITAL FOR SPECIAL SURGERY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shah is a mixed practice specialist, with above-average Medicare volume (top 3% in NY), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Shah performed 30,460 oxaliplatin chemotherapy injection services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $304,792 from 34 companies across 213 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other medical oncologists in New York?
Dr. Shah's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in New York
Browse medical oncologists in New York ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NY
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NY
Which NY medical oncologists receive the most from drug and device companies.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology